查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963954

个人化医疗生物标记市场－全球产业规模、份额、趋势、机会、预测：按应用、疾病、地区和竞争格局划分，2021-2031年

Personalized Medicine Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Indication, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球个人化医疗生物标记市场预计将从 2025 年的 159.9 亿美元成长到 2031 年的 233.4 亿美元，复合年增长率为 6.51%。

这些生物标誌物，包括基因、蛋白质和基因突变等特定生物分子，对于识别特定治疗性介入的最佳患者亚群以及预测不良反应至关重要。该市场的成长主要得益于基因测序技术的快速发展以及医疗保健模式向标靶治疗的模式转移，后者旨在最大限度地提高疗效并最大限度地降低毒性。癌症等慢性疾病的日益普遍以及伴随诊断在药物研发中的应用不断扩大，进一步加速了这一转变。根据个人化医疗联盟（Personalized Medicine Coalition）统计，美国食品药物管理局（FDA）在2024年核准了18种新的个人化药物，约占新核准治疗性分子实体的38%，凸显了该领域在现代医学中日益增长的影响力。

市场概览
预测期 2027-2031
市场规模：2025年 159.9亿美元
市场规模：2031年 233.4亿美元
复合年增长率：2026-2031年 6.51%
成长最快的细分市场 肿瘤学
最大的市场 北美洲

儘管生物标记检测具有巨大的成长潜力，但其复杂的报销环境为市场带来了重大障碍。支付者往往难以评估生物标记检测的价值，导致保险覆盖政策不一致，限制了患者获得这些关键诊断工具的机会。此外，开发和检验新型生物标记的高昂成本也对小规模的生物技术公司构成了巨大的财务障碍。因此，儘管科学创新不断加速，但监管核准和报销机制之间的不一致仍然是一个重大挑战，有可能减缓个人化医疗解决方案在全球范围内的商业性化应用。

市场驱动因素

次世代定序和基因组学技术的快速发展正在推动市场成长，实现了基因突变和表现模式的高通量识别。这些技术进步使研究人员能够分析大量的遗传资讯资料集，加速发现对精准医疗发展至关重要的新型生物标记。利用强大的定序基础设施进行疾病感受性作图和治疗标靶识别的领先倡议，展现了大规模处理基因组数据的能力。根据英国生物银行于2023年11月发布的全球最大规模的基因资料发布，来自50万名参与者的全基因测序资料已向核准研究人员开放。这是进行遗传标记与健康结果之间相关性分析的重要资源，有助于缩短将研究成果转化为临床工具的时间。

同时，全球癌症和慢性病发病率的上升对市场产生了重大影响，使得标靶治疗的引入对于提高患者存活率至关重要。面对日益沉重的复杂疾病负担，医疗系统正越来越多地利用生物标记对患者进行分层，并选择合适的治疗性介入。根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》报告，预计仅2024年美国就将新增2,001,140例癌症病例，凸显了精准诊断技术的紧迫性。疾病发生率的上升迫使製药公司优先考虑以生物标记主导的药物研发。例如，阿斯特捷利康于2024年2月发布的《2023财年年度报告及20-F表格资讯》指出，其临床开发平臺中约90%为标靶治疗，这反映了整个产业向个人化医疗的转变。

市场挑战

复杂的诊断检测报销机制严重阻碍因素了全球个人化医疗生物标记市场的发展。支付者和保险公司常常难以对这些先进的诊断技术应用统一的价值评估框架，导致保险覆盖范围难以预测，拒保率居高不下。这种不确定性给医疗服务提供者带来了挑战，可能导致他们因行政障碍和潜在的经济责任而犹豫是否进行必要的生物标记检测。因此，新型生物标记的商业性可行性受到损害，相关标靶治疗的推出也被显着延缓。

保险覆盖范围的不匹配直接阻碍了市场渗透，影响了诊断的可及性和患者的就医途径。缺乏可靠的报销机制，个人化医疗的普及程度仍不尽人意，限制了研发者的商机。根据个人化医疗联盟（Personalized Medicine Coalition）预测，到2024年，仅有36%的进行性非小细胞肺癌患者（他们可能受益于个人化医疗）能够获得治疗，这凸显了这些就医障碍的严重影响。这些数据表明，儘管科学取得了突破性进展，但报销模式未能跟上临床创新步伐，严重阻碍了市场成长。

市场趋势

液态生物检体的日益普及正推动市场从静态组织取样转向动态、非侵入性监测。这项技术能够检测循环肿瘤DNA并即时识别抗药性机制，使临床医生能够在避免重复切片检查风险的前提下调整治疗方案。随着治疗方案选择和復发追踪中对血液检测的依赖性不断增强，液体活检的商业性发展势头也日益强劲。根据Guardant Health于2024年5月发布的2024年第一季财报，临床检测量年增20%至46,900例，显示精准医疗管理中对液态生物检体的依赖性日益增强。

同时，人工智慧的引入正在革新整合多模态资料集的生物标记发现方法。计算工具分析基因组数据和临床数据之间的相互作用，识别出传统方法忽略的预测性特征，从而提高临床试验的成功率。这种数据驱动方法建构的庞大资料库为演算法诊断和个人化医疗策略提供了支援。 Tempus AI在2024年5月向美国证券交易委员会提交的S-1表格註册声明中披露，其多模态资料库的资料量已超过Petabyte，这充分展现了支撑生物标誌物开发的数位基础设施的庞大规模。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：个人化医疗生物标记的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按应用领域（早期检测/筛检、适应症、治疗选择、监测）
    • 疾病特定类别（肿瘤科、神经科、糖尿病科、自体免疫疾病科、心臟科、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美个人化医疗生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲个人化医疗生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区个人化医疗生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲个人化医疗生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲个人化医疗生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球个人化医疗生物标记市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Laboratory Corporation of America Holding
  • Quest Diagnostics Incorporated
  • Agilent Technologies, Inc.
  • Genome Medical, Inc.
  • Coriell Life Sciences.
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories, Inc.
  • FOUNDATION MEDICINE, INC.
  • Illumina, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23939

The Global Personalized Medicine Biomarkers Market is projected to expand from USD 15.99 Billion in 2025 to USD 23.34 Billion by 2031, reflecting a CAGR of 6.51%. These biomarkers, which include specific biological molecules like genes, proteins, or genetic variations, are essential for identifying patient subgroups best suited for particular therapeutic interventions or for predicting adverse reactions. The market is primarily driven by rapid breakthroughs in genomic sequencing technologies and a healthcare paradigm shift toward targeted therapies that maximize treatment efficacy while minimizing toxicity. This transition is further reinforced by the rising prevalence of chronic conditions such as cancer and the increasing incorporation of companion diagnostics into drug development. According to the Personalized Medicine Coalition, the U.S. FDA approved 18 new personalized medicines in 2024, accounting for approximately 38 percent of all newly authorized therapeutic molecular entities, highlighting the sector's growing impact on modern medicine.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 15.99 Billion
Market Size 2031USD 23.34 Billion
CAGR 2026-20316.51%
Fastest Growing SegmentOncology
Largest MarketNorth America

Despite this strong growth potential, the market faces significant hurdles due to the complicated reimbursement landscape for diagnostic tests. Payers often find it difficult to assess the value of biomarker testing, resulting in inconsistent coverage policies that restrict patient access to these critical diagnostic tools. Additionally, the substantial costs involved in developing and validating novel biomarkers present a high financial barrier for smaller biotechnology firms. Consequently, while scientific innovation continues to accelerate, the misalignment between regulatory approval and reimbursement mechanisms remains a critical challenge that threatens to slow the widespread commercial adoption of personalized medicine solutions globally.

Market Driver

Rapid advancements in next-generation sequencing and genomic technologies act as a primary catalyst for the market, enabling high-throughput identification of genetic mutations and expression patterns. These technical improvements allow researchers to analyze immense datasets of genetic information, facilitating the discovery of novel biomarkers crucial for developing precision therapies. The capacity to process genomic data at scale is demonstrated by major initiatives that utilize robust sequencing infrastructure to map disease susceptibility and pinpoint therapeutic targets. According to the UK Biobank, in its November 2023 announcement regarding the release of the world's largest genetic dataset, whole genome sequencing data from 500,000 participants was made available to approved researchers, providing a vital resource for correlating genetic markers with health outcomes and shortening the timeline for translating insights into clinical tools.

Simultaneously, the market is heavily influenced by the rising global prevalence of cancer and chronic diseases, which necessitates the adoption of targeted treatment regimens to enhance patient survival rates. As the burden of complex pathologies increases, healthcare systems increasingly rely on biomarkers to stratify patients and select appropriate therapeutic interventions. According to the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024, it is projected that there will be 2,001,140 new cancer cases in the United States alone in 2024, underscoring the urgent need for precise diagnostic modalities. This growing disease incidence compels pharmaceutical companies to prioritize biomarker-driven drug development; for instance, AstraZeneca's 'Annual Report and Form 20-F Information 2023' from February 2024 noted that approximately 90 percent of its clinical pipeline consisted of targeted therapies, reflecting an industry-wide commitment to personalized medicine.

Market Challenge

The intricate reimbursement landscape for diagnostic tests operates as a severe constraint on the growth of the Global Personalized Medicine Biomarkers Market. Payers and insurers frequently struggle to apply consistent value assessment frameworks to these advanced diagnostics, leading to unpredictable coverage decisions and high denial rates. This uncertainty creates a difficult environment for healthcare providers, who may hesitate to order essential biomarker tests due to administrative hurdles and potential financial liabilities. As a result, the commercial viability of novel biomarkers is compromised, and the uptake of associated targeted therapies is significantly delayed.

This misalignment in coverage directly impedes market penetration by disconnecting diagnostic availability from patient access. Without reliable reimbursement pathways, the adoption of personalized medicine remains suboptimal, limiting revenue opportunities for developers. According to the Personalized Medicine Coalition, in 2024, personalized medicines reached only 36 percent of potentially eligible advanced non-small cell lung cancer patients, highlighting the profound impact of these access barriers. Such data illustrates that despite scientific breakthroughs, the market's trajectory is heavily suppressed by the inability of reimbursement models to keep pace with clinical innovation.

Market Trends

The widespread adoption of liquid biopsy is transitioning the market from static tissue sampling to dynamic, non-invasive monitoring. This technology detects circulating tumor DNA to identify resistance mechanisms in real time, enabling clinicians to adjust treatments without the risks associated with repeat biopsies. Commercial momentum is accelerating as providers increasingly rely on blood-based testing for therapy selection and recurrence tracking. According to Guardant Health's 'First Quarter 2024 Financial Results' press release in May 2024, the company reported a 20 percent year-over-year increase in clinical test volume to 46,900 tests, illustrating the growing dependence on liquid biopsy for precision management.

At the same time, the implementation of artificial intelligence is reshaping biomarker discovery by integrating multi-modal datasets. Computational tools analyze interactions between genomic and clinical data to identify predictive signatures that traditional methods overlook, thereby increasing the success rates of clinical trials. This data-driven approach creates extensive libraries that fuel algorithmic diagnostics and personalized care strategies. According to Tempus AI, in its 'Form S-1 Registration Statement' filed with the U.S. Securities and Exchange Commission in May 2024, the organization disclosed that its multimodal database grew to include over 200 petabytes of data, demonstrating the massive scale of digital infrastructure now supporting biomarker development.

Key Market Players

  • Laboratory Corporation of America Holding
  • Quest Diagnostics Incorporated
  • Agilent Technologies, Inc.
  • Genome Medical, Inc.
  • Coriell Life Sciences.
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories, Inc.
  • FOUNDATION MEDICINE, INC.
  • Illumina, Inc.

Report Scope

In this report, the Global Personalized Medicine Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Personalized Medicine Biomarkers Market, By Application

  • Early Detection/Screening
  • Indication
  • Treatment Selection
  • Monitoring

Personalized Medicine Biomarkers Market, By Indication

  • Oncology
  • Neurology
  • Diabetes
  • Autoimmune Diseases
  • Cardiology
  • Others

Personalized Medicine Biomarkers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Personalized Medicine Biomarkers Market.

Available Customizations:

Global Personalized Medicine Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Personalized Medicine Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Early Detection/Screening, Indication, Treatment Selection, Monitoring)
    • 5.2.2. By Indication (Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Personalized Medicine Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Indication
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Personalized Medicine Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Indication
    • 6.3.2. Canada Personalized Medicine Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Indication
    • 6.3.3. Mexico Personalized Medicine Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Indication

7. Europe Personalized Medicine Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Indication
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Personalized Medicine Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Indication
    • 7.3.2. France Personalized Medicine Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Indication
    • 7.3.3. United Kingdom Personalized Medicine Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Indication
    • 7.3.4. Italy Personalized Medicine Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Indication
    • 7.3.5. Spain Personalized Medicine Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Indication

8. Asia Pacific Personalized Medicine Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Indication
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Personalized Medicine Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Indication
    • 8.3.2. India Personalized Medicine Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Indication
    • 8.3.3. Japan Personalized Medicine Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Indication
    • 8.3.4. South Korea Personalized Medicine Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Indication
    • 8.3.5. Australia Personalized Medicine Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Indication

9. Middle East & Africa Personalized Medicine Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Indication
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Personalized Medicine Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Indication
    • 9.3.2. UAE Personalized Medicine Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Indication
    • 9.3.3. South Africa Personalized Medicine Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Indication

10. South America Personalized Medicine Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Indication
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Personalized Medicine Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Indication
    • 10.3.2. Colombia Personalized Medicine Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Indication
    • 10.3.3. Argentina Personalized Medicine Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Personalized Medicine Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Laboratory Corporation of America Holding
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Quest Diagnostics Incorporated
  • 15.3. Agilent Technologies, Inc.
  • 15.4. Genome Medical, Inc.
  • 15.5. Coriell Life Sciences.
  • 15.6. Thermo Fisher Scientific Inc.
  • 15.7. NeoGenomics Laboratories, Inc.
  • 15.8. FOUNDATION MEDICINE, INC.
  • 15.9. Illumina, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer